Q2 EPS Estimate for Ovid Therapeutics Raised by Analyst

Ovid Therapeutics Inc. (NASDAQ:OVID) – Equities researchers at William Blair upped their Q2 2025 earnings per share (EPS) estimates for Ovid Therapeutics in a note issued to investors on Tuesday, November 12th. William Blair analyst S. Schram now forecasts that the company will post earnings of $0.23 per share for the quarter, up from their previous estimate of $0.16. William Blair has a “Strong-Buy” rating on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.49) per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $3.00 price objective on shares of Ovid Therapeutics in a research note on Monday, September 30th. Two analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $4.04.

Ovid Therapeutics Trading Down 5.7 %

Ovid Therapeutics stock opened at $1.15 on Thursday. Ovid Therapeutics has a 12-month low of $0.68 and a 12-month high of $4.10. The firm has a market capitalization of $81.62 million, a price-to-earnings ratio of -2.60 and a beta of 0.41. The firm has a 50 day moving average of $1.16 and a 200 day moving average of $1.56. The company has a current ratio of 5.73, a quick ratio of 5.73 and a debt-to-equity ratio of 0.16.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Tuesday, August 13th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.22) by $0.34. The firm had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.14 million. Ovid Therapeutics had a negative return on equity of 38.24% and a negative net margin of 5,142.56%.

Institutional Investors Weigh In On Ovid Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of OVID. Price T Rowe Associates Inc. MD boosted its position in shares of Ovid Therapeutics by 22.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 17,396 shares of the company’s stock valued at $54,000 after acquiring an additional 3,145 shares during the last quarter. Empowered Funds LLC lifted its position in Ovid Therapeutics by 8.1% during the first quarter. Empowered Funds LLC now owns 128,070 shares of the company’s stock valued at $391,000 after purchasing an additional 9,625 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Ovid Therapeutics by 74.7% in the 1st quarter. BNP Paribas Financial Markets now owns 32,162 shares of the company’s stock worth $98,000 after buying an additional 13,756 shares in the last quarter. DCF Advisers LLC grew its stake in shares of Ovid Therapeutics by 111.6% in the 2nd quarter. DCF Advisers LLC now owns 41,750 shares of the company’s stock worth $32,000 after buying an additional 22,020 shares in the last quarter. Finally, FMR LLC increased its holdings in shares of Ovid Therapeutics by 1,907.4% in the 3rd quarter. FMR LLC now owns 50,225 shares of the company’s stock worth $59,000 after buying an additional 47,723 shares during the last quarter. Institutional investors own 72.24% of the company’s stock.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.